New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
16:39 EDTTLYS, AET, ZLC, VVUS, STJ, SQNM, CRMOn The Fly: Closing Wrap
Stocks on Wall Street were higher on the day, the last full trading session of the week ahead of Thursday's holiday and Friday's half day. Jobless data that was in-line with expectations did little to move the markets before the open, but the markets slowly moved higher through the session, although volume remained light. Just after midday, news crossed that a cease fire between Israel and Hamas had been reached, tempering fears that the conflict could escalate to involve other players in the region and have broader economic impacts... ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 410,000, which was in-line with forecasts. Markit's "flash" November flash PMI rose to 52.4 from 51.0 in October. The final November reading of the University of Michigan Sentiment index slipped to 82.7 from its 84.9 preliminary reading. The leading indicators edged up 0.2% in October to 96.0 from 95.8 in September. In Europe, the region's finance ministers and the IMF were unable to reach a bailout agreement for Greece and will meet again on Monday with an eye on resolving the remaining disagreements. In Asia, Japanese exports fell 6.5% in October, lower than expectations for a 4.9% decline... COMPANY NEWS: Salesforce.com's (CRM) Q3 results beat on the top and bottom lines and RW Baird and Wells Fargo reiterated their Outperform ratings on the stock following the report, and shares of Salesforce.com traded higher on the session, settling up $12.88, or 8.83%, to $158.78... MAJOR MOVERS: Among notable gainers were shares of VIVUS (VVUS), up $1.38, or 13.33%, to $11.73 after Aetna (AET) posted a policy revision that expands coverage of the company's weight-loss drug Qsymia. Also higher were shares of Sequenom (SQNM), up 56c, or 15.18%, to $4.25 after a committee of the American College of Obstetricians and Gynecologists recommended that cell-free fetal DNA testing be offered to certain at-risk patients. Among the noteworthy were shares of Zale (ZLC), down over $2.23, or 29.97%, to $5.21, and Tilly's (TLYS), down $2.69, or 17.18%, to $12.97 after reporting earnings. Also lower were shares of St. Jude Medical (STJ), which fell $4.34, or 12.15%,to $31.37 after an FDA inspection report cited serious flaws in its oversight of design changes in its Durata line of defibrillator leads... INDICES The Dow was up 48.38, or 0.38%, to 12,836.89; the S&P 500 was up 3.22, or 0.23%, to 1,391.03;the Nasdaq was up 9.87, or 0.34%, to 2,926.55.
News For CRM;VVUS;AET;SQNM;ZLC;TLYS;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 1, 2016
06:04 EDTAETAetna reports Q4 Health Care business revenue $14.4B
Reports Q4 Group Insurance revenue $618.3M. Reports Q4 Large Case Pensions revenue $67.5M.
06:03 EDTAETAetna on track to close Humana transaction in 2H16
The company commented, "We continue to work diligently with the Department of Justice and state regulators toward final approval of our proposed acquisition of Humana, and we continue to advance our integration readiness plans. We have obtained seven of the necessary state approvals, and we believe we remain on track to close the transaction in the second half of 2016."
06:02 EDTAETAetna sees FY16 operating EPS of at least $7.75, consensus $8.05
06:01 EDTAETAetna reports medical membership totaled 23.5M at December 31, 2015
Subscribe for More Information
06:01 EDTAETAetna reports Q4 operating EPS $1.37, consensus $1.21
Reports Q4 revenue $15.09B, consensus $14.93B.
January 29, 2016
14:24 EDTAETEarnings Watch: Aetna down 9% since last report
Aetna (AET) is scheduled to report fourth quarter earnings before the market open on Monday, February 1, with a conference call scheduled for 8:30 am ET. Aetna, a diversified health care benefits company in the United States, operates in three segments: Health Care, Group Insurance, and Large Case Pensions. EXPECTATIONS: Analysts are looking for earnings per share of $1.21 on revenue of $14.93B, according to First Call. The consensus range for EPS is $1.16-$1.32 on revenue of $14.44B-$15.36B. LAST QUARTER: Aetna reported third quarter EPS of $1.90 on revenue of $14.97B against analyst estimates of $1.77 and $14.95B, respectively. The company raised its fiscal 2015 EPS view to $7.45-$7.55 from "at least $7.40." Operating earnings were $668.6M for Q315 compared with $638.6M for Q314. The increase in operating earnings was primarily due to higher underwriting margins in Aetna's Health Care segment, partially offset by an increase in general and administrative expenses and lower underwriting margins in Aetna's Group Insurance segment. On January 11, Aetna said it see FY15 EPS at the high end of the $7.45-$7.55 range. Consensus for FY15 EPS is $7.54. STREET RESEARCH: On January 15, Wells Fargo said it expects health insurers' stock to do well this year, as the firm expects M&A deals made the last years to increase profits this year, and it thinks investors should be attracted to what it sees as the defensive names in the sector. Wells does not believe that any changes to or replacements of the ACA will be worse for the sector than the status quo. It identified Aetna and HCA Holdings (HCA) as its favorite names in the sector. On January 25, Leerink analyst Ana Gupte said she believed the recent selloff has provided a "strong" buying opportunity in the Managed Care space. Valuations are attractive on multiple metrics, Gupte told investors in a research note. Her top picks are UnitedHealth (UNH), Aetna, Humana (HUM) and Molina Healthcare (MOH). The analyst also favors Anthem (ANTM) and Cigna (CI). PRICE ACTION: Shares of Aetna are down approximately 9% since its last earnings report. The stock is up 2.6% to $101.42 in Friday afternoon trading ahead of Monday morning's report.
13:10 EDTAETAetna technical comments ahead of earnings
Subscribe for More Information
10:16 EDTCRMOptions with increasing implied volatility: WMB W CERS RAD CRM GILD MNST
Subscribe for More Information
07:03 EDTAETAetna volatility elevated into Q4 and outlook
Aetna February weekly call option implied volatility is at 47, February and March is at 38; compared to its 52-week range of 18 to 44, suggesting large near term price movement into the expected release of Q4 results on February 1.
05:09 EDTCRMStocks with implied volatility above IV index mean; CRM TWTR
Stocks with implied volatility above IV index mean; Salesforce (CRM) 46, Twitter (TWTR) 95 according to iVolatility.
January 28, 2016
17:01 EDTAETAetna enters four-year reinsurance arrangement with Vitality Re VII
Aetna announced it has entered into a four-year reinsurance arrangement with Vitality Re VII. The arrangement allows Aetna to reduce its required capital and provides $200M of collateralized excess of loss reinsurance coverage on a portion of Aetna's group commercial health insurance business.
11:11 EDTSTJHeartWare rallies after scrapping Valtech acquisition
The shares of HeartWare (HTWR) are surging after the company announced that would terminate its acquisition of privately held Valtech. Two research firms reacted positively to the news, with Leerink Swann saying that the company made the right decision, given its current difficulties and Raymond James upgrading HeartWare following the news. HeartWare develops and manufactures miniaturized implantable heart pumps, while Valtech has developed a method of replacing mitral valves in human hearts without the need for open heart surgery. WHAT'S NEW: HeartWare decided to terminate its acquisition of Valtech, the companies announced this morning. Pursuant to the terms of the agreement, HeartWare will make a $30M loan to Valtech in the form of a convertible promissory note. ANALYST REACTION: HeartWare's decision to abandon its acquisition of Valtech was correct in light of the problems that the company is facing with its next generation MVAD pump, Leerink analyst Danielle Antalffy wrote in a note to investors today. Noting that two weeks ago HeartWare announced that it would investigate suction issues that the device has had, the analyst says that fixing the pump could require additional investment, while it's uncertain how long it will take to solve the device's problems. However, the analyst remained upbeat on Heartware's current LVAD products, and believes that it can compete with next generation systems. She kept a $60 price target and Outperform rating on the shares. Raymond James upgraded HeartWare to Outperform from Market Perform, saying that the termination of the Valtech deal removes an overhang on the shares, while the stock's underperformance since September has made its valuation more attractive. Moreover, the stock does not appear to be giving any value to the problematic MVAD pump and the company has a 37% share of a $760M market that has only two main competitors and high barriers to entry, the firm wrote. WHAT'S NOTABLE: In early October 2015, activist investor Engaged Capital urged HeartWare to terminate the Valtech deal. Today HeartWare announced that it would, in conjunction with Engaged Capital, "jointly select" an independent party who will join Heartware's board. ANOTHER TO WATCH: HeartWare's chief rival, Thoratec, was acquired last year by St. Jude Medical (STJ). PRICE ACTION: In late morning trading, HeartWare rose 10% to $37.95. St. Jude, which reported its fourth quarter results and gave fiscal year guidance this morning, is down 1.4% to $53.56.
January 27, 2016
08:50 EDTSTJSt. Jude Medical sees FY16 CardioMEMS sales about $65M
Subscribe for More Information
07:19 EDTSTJSt. Jude Medical sees FY16 sales growth 2%-4%, consensus $6.12B
Subscribe for More Information
07:19 EDTSTJSt. Jude Medical sees Q1 adjusted EPS 87c-98c, consensus 94c
07:18 EDTSTJSt. Jude Medical reports Q4 CRM sales $580M, down 15% y/y
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q4 adjusted EPS $1.02, consensus $1.01
Reports Q4 revenue $1.47B, consensus $1.47B.
January 26, 2016
14:32 EDTSTJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Novartis (NVS), consensus $1.18... Boeing (BA), consensus $1.26... United Technologies (UTX), consensus $1.52... Biogen (BIIB), consensus $4.08... EMC (EMC), consensus 65c... General Dynamics (GD), consensus $2.38... Anthem (ANTM), consensus $1.22... Illinois Tool Works (ITW), consensus $1.21... State Street (STT), consensus $1.18... Norfolk Southern (NSC), consensus $1.24... Progressive (PGR), consensus 47c... St. Jude Medical (STJ), consensus $1.01... Rockwell Automation (ROK), consensus $1.33... Textron (TXT), consensus 83c... Hess (HES), consensus ($1.47)... Cliffs Natural (CLF), consensus (26c).
07:36 EDTCRMKKR leads funding round in Jitterbit
Subscribe for More Information
07:04 EDTSTJSt. Jude Medical volatility flat into Q4 and outlook
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use